They validated EHD3, TMEM240, and SMAD3 on blood plasma samples from an independent group of CRC patients using the methods most accessible for clinics, namely, methyl-specific/methyl-sensitive PCR (Table 2). This evidence concerns the gene TMEM240 and colorectal carcinoma.